Retrospective Cohort Study
Copyright ©The Author(s) 2019. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Clin Oncol. Feb 24, 2019; 10(2): 75-85
Published online Feb 24, 2019. doi: 10.5306/wjco.v10.i2.75
Retrospective evaluation of FOLFIRI3 alone or in combination with bevacizumab or aflibercept in metastatic colorectal cancer
Madeline Devaux, Laura Gerard, Corentin Richard, Leila Bengrine-Lefevre, Julie Vincent, Antonin Schmitt, François Ghiringhelli
Madeline Devaux, Laura Gerard, Leila Bengrine-Lefevre, Julie Vincent, Antonin Schmitt, François Ghiringhelli, Department of Medical Oncology, Centre George François Leclerc, Dijon 21000, France
Corentin Richard, François Ghiringhelli, Platform of Transfer in Biological Oncology, Centre George François Leclerc, Dijon 21000, France
Author contributions: Devaux M, Gerard L, Bengrine-Lefevre L and Vincent J contributed to data acquisition; Ghiringhelli F and Richard C contributed to data interpretation; Richard C contributed to statistical analyses; Ghiringhelli F and Richard C contributed to manuscript drafting; all authors contributed to manuscript revision and final approval.
Institutional review board statement: The database was declared to the National French Commission for bioinformatics data and patient liberty (CNIL). The study was performed in accordance with French regulations with approval from the local institutional review boards.
Informed consent statement: A general informed consent was signed by all cancer patients at the time of their first hospitalization in the cancer centre. This consent allows the use of their clinical and biological data in the cohort study.
Conflict-of-interest statement: The authors declare that they have no competing interests.
STROBE statement: The STROBE Statement has been adopted.
Open-Access: This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Corresponding author: François Ghiringhelli, MD, Professor, Department of Medical Oncology, Centre George François Leclerc, 1 Rue du Professeur Marion, Dijon 21000, France. fghiringhelli@cgfl.fr
Telephone: +33-380-732424 Fax: +33-380-737500
Received: October 17, 2018
Peer-review started: October 17, 2018
First decision: November 27, 2018
Revised: December 31, 2018
Accepted: January 23, 2019
Article in press: January 23, 2019
Published online: February 24, 2019
Core Tip

Core tip: This retrospective study suggests that modified FOLFIRI with injection of irinotecan at day 1 and 3 is interesting for patients with previously treated metastatic colorectal cancer. Surprisingly the efficacy of the FOLFIRI3-aflibercept seems superior the FOLFIRI3 alone or in combination with bevacizumab. Prospective randomized trial comparing FOLFIRI-aflibercept to FOLFIRI3-aflibercept in second line are warranted.